#### APPENDIX I. PHARMACY AUDIT REPORT

### DCP PROJECT PHARMACY AUDIT REPORT

#### I. SITE INFORMATION

**Instructions:** Please provide the requested information for each of the items listed below. Provide comments whenever necessary or helpful.

Name of Clinical Site:

Protocol Name:

Document Number:

Name and Address of Pharmacy:

Date of Audit:

Conducted by:

Investigational Pharmacy Personnel:

NAME	TITLE	MET WITH MONITOR (Y/N)
	Pharmacist of Record	
	Other Staff / Title	

**Additional Comments:** 

### II. MAINTENANCE OF RECORDS

**Instructions:** Please provide the requested information for each of the items listed below ("Y" = Yes, "N" = No). Please provide comments whenever necessary or helpful.

<b>ITEMS VERIFIED and/or DISCUSSED</b>	Y	Ν	*NA	COMMENTS		
A. Are the following protocol-specific documents present?						
1. Form FDA 1572						
2. Prescriber signature list						
3. Most recent version of the protocol for which the site has IRB approval						
4. Participant study assignment list						
5. Drug ordering instructions						
B. Are the following records accessible only to the site pharmacist or his/her designee?						
1. Study assignment lists						
2. Investigational agent accountability/ inventory records						
3. Order forms/shipping receipts						
4. Participant-specific profiles, if used						

### III. SECURITY AND STORAGE OF THE INVESTIGATIONAL DRUGS

ITEMS VERIFIED and/or DISCUSSED	Y	Ν	*NA	COMMENTS	
A. Inspect the investigational drug storage area.					
<ol> <li>Are the investigational drugs stored according to the manufacturer's specifications?</li> </ol>					
2. Are supplies sufficient?					
3. Outdated drugs are not stored together with the active drug supply.					
4. Is refrigerator and/or freezer storage available?					
a. If yes, describe location of refrigerator and/or freezer and method of monitoring temperature.					
5. Is study drug stored in a secure, limited access area?					

# IV. DRUG ACCOUNTABILITY, PREPARATION AND DISPENSATION

<b>ITEMS VERIFIED and/or DISCU</b>	SSED	Y	Ν	*NA		COMMENTS
A. Accountability						
1. Do the increases in drug inventory o	n the					
investigational accountability record	S					
agree with the shipment receipts?						
2. Are the accountability records legibl						
complete with each entry initialed by						
pharmacists of record or other author	rized					
personnel?						
3. Are there any entries in the accounta	bility					
records that indicate dispensing of	.1					
investigational agents to persons othe						
participants enrolled in this/these stu						
4. If study drug is commercially available						
are procedures in place to assure that drug is not stored together with the g						
supply?	eneral					
5. Does the inventory balance documer	nted on					
the accountability record correspond						
precisely with the actual physical						
inventory?						
	the ager	nt cou	inted	as we	Il as the amount	recorded on the accountability record for
each discrepancy noted						
Drug	Acco	untak	oility	Recor	d	Inventory Amount
Explanation/Discussion						
6. Is the amount of drug supply on hand	d					
reasonable based on current enrollme	ent and					
accrual rate?						

# IV. DRUG ACCOUNTABILITY, PREPARATION AND DISPENSATION (continued)

ITEMS VERIFIED and/or DISCUSSED	Y	Ν	*NA	COMMENTS
B. Drug Preparation and Dispensing				
1. Describe the routine procedure for dispensing study drugs.				
a. When, in relation to the participant study visit, is the study drug prepared? Describe:				
b. How does the investigational pharmacist usually receive study drug prescriptions? Describe:				
c. To whom does the investigational pharmacist dispense study drugs? Describe:				

## **Additional Comments:**

Prepared by:

(Signature)

Date: